openPR Logo
Press release

New Report Examines the Global Outlook for Platelet Aggregation Inhibitors Market Analysis to 2027

07-20-2017 02:59 PM CET | Health & Medicine

Press release from: Transparency Market Research

New Report Examines the Global Outlook for Platelet Aggregation

Platelet are blood cells, which make up small volume of the blood and prevents bleeding. Platelet-aggregation inhibiting drugs prevent blood clot inside of the body as during atherosclerosis. Platelet aggregation inhibitors are antiplatelet drugs prescribed during coronary artery diseases, chest pain, stroke, periphery artery disease (PAD), etc. It is also used during heart bypass surgery, atrial fibrillation, after angioplasty and stent placement. Platelet aggregation is the biological process, mediated by PAF (platelet activation factor).

Platelet aggregation inhibitors are used during thrombocytosis that occur during hematologic diseases, cancer, and other chronic infections. Aspirin, antiplatelet drug is most commonly used as it changes the balance between prostacyclin and thromboxane, antiplatelet drug inhibits enzyme cyclooxygenase, which reduces prostacyclin in vascular endothelial cells and thromboxane synthesis in platelet.

Browse Market Research Report @ http://www.transparencymarketresearch.com/platelet-aggregation-inhibitors-market.html

Major cause of platelet aggregation are high triglycerides, lack of exercise, improper diet and sedentary lifestyle. Research scientists have turned to technologically advanced technique for increased efficacy of platelet aggregation inhibitor drugs that reflects positive growth of the market. Many heart and stroke patients are treated by dual antiplatelet therapy using two types of antiplatelet agents known as aspirin and P2Y12 inhibitor.

Platelet aggregation test is performed before prescribing anticoagulants, as it helps to determine the platelet clotting efficiency, some platelet aggregation cause serious problems and contribute to cardiovascular diseases. Patients with diabetes and high cholesterol (hypercholesterolemia) demonstrate increased platelet aggregation capacity and expose them to clotting disorders followed by vessel obstruction and thrombus.

Hypercholesterolaemia (high cholesterol) is one of the major cause of death globally, about 2.6 million death occur per year worldwide. According to world health organization, in the European Union five biggest countries - Germany, France, Italy, Spain and UK, 133 million people suffer from bad cholesterol. New generation platelet aggregation inhibitors are more rapid in action with increased absorption with improved efficacy which will drive the growth of the platelet aggregation inhibitor market in the near future.

Factors such as increased risk of cardiovascular diseases, technological advancements in the development of platelet aggregation inhibitor drugs, increase in clinical studies due to potent platelet aggregation inhibitor drug candidates in the pipeline, cost effective drugs and increased expenditure on healthcare sector are some of the factors fuelling the growth of the global platelet aggregation inhibitor market. Some factors such as unfavorable healthcare reforms, lack of awareness and skilled professionals, patent expiration, high development cost are some factors inhibiting the growth of target market.

The platelet aggregation inhibitor market is segment based on application, route of administration distribution channel and geography. Based on the application type, the platelet aggregation inhibitor market is segmented into venous thromboembolism (VTE), acute coronary syndrome/ myocardial infarction, and atrial fibrillation (AF). On the basis of route of administration, the platelet aggregation inhibitor market is segmented into injection and oral. Based on distribution channel, the platelet aggregation inhibitor market is segmented into hospital pharmacy, retail pharmacy, drug stores, and online pharmacy.

Increase in the number of patient population and lifestyle diseases will boost the platelet aggregation inhibitors market. Growth opportunities such as increasing market share through mergers and acquisitions, investing in emerging economics, technological advancement and patent expiration will facilitate the small players to develop generic version of platelet aggregation inhibitor drugs that will boost the growth of the platelet aggregation inhibitor market.

For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25946

Region wise, the platelet aggregation inhibitor market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is estimated to account for major share followed by European countries. Mainly the U.S. & European markets, is estimated to maintain leadership geographically, owing to its innate nature of developed healthcare infrastructure, adopts advanced technology at early stage as compared to developing economies, high pricing of drugs, increase in incidence of lifestyle diseases such as cancer, hematology diseases, CVD and others, that follows large patient pool. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as rising standard of living, lifestyle changes and focusing on healthcare expenditures.

Some of the key players in global platelet aggregation inhibitor market are Sanofi S.A., Bristol-Myers Squibb, Pfizer Inc., Bayer AG, Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Genentech, Inc., DAIICHI SANKYO COMPANY, LIMITED, AstraZeneca plc. and others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Report Examines the Global Outlook for Platelet Aggregation Inhibitors Market Analysis to 2027 here

News-ID: 634514 • Views:

More Releases from Transparency Market Research

Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn
Digital Health Market Estimated at US$ 1.1 Trillion by 2031, TMR Study
Digital Health Market Estimated at US$ 1.1 Trillion by 2031, TMR Study
In 2022, the worldwide 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 garnered a valuation of US$ 382.5 billion. Projections indicate a steady growth trajectory, with a compound annual growth rate (CAGR) of 13.1% anticipated from 2023 to 2031, ultimately culminating in a total valuation of US$ 1.1 trillion by the conclusion of 2031. Market analysts foresee a promising outlook characterized by the burgeoning prevalence of chronic diseases and the increasing adoption of smartphones and internet
Global Data Center Networking Market Set to Surge, Forecasted to Reach US$ 56.3 …
The Data Center Networking Market is poised for remarkable growth, driven by the burgeoning demand for cloud-native applications and the rapid adoption of data center virtualization and cloud computing. With an estimated value of US$20.6 billion in 2021, the market is projected to surge at a robust CAGR of 10.8% from 2022 to 2031, reaching a staggering US$56.3 billion by the end of 2031. Get Sample Copy of This Report at:

All 5 Releases


More Releases for Platelet

Global Platelet aggregation reagents Market Growth 2019-2024
Market Research Report Store offers a latest published report on Platelet aggregation reagents Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Platelet aggregation reagents players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Platelet aggregation reagents with
Platelet, Plasma Market
Platelet, Plasma Market is estimated to surpass $ 6.3 Billion markets in 2019 and reach USD 14.56 Billion by 2024, at a Compound Annual Growth Rate (CAGR) of 3.2% during the forecast period 2016-2024 globally. For More Information Visit https://www.maximizemarketresearch.com/market-report/platelet-plasma-market/11293/ A rising incidence of haemophilia, thrombocytopenia, autoimmune diseases as well as other infectious and rare disease will serve to be a key driver for the platelet and plasma market growth. According
Platelet Rich Plasma Market By PRP Type (Pure-PRP, Leucocyte Rich PRP, Pure Plat …
Platelet rich plasma (PRP) is a portion of the plasma fraction of analogous blood, which contains platelet concentration more than standard concentration. Platelets contains bio proteins that helps in healing, tissue regeneration, and blood loss. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. The use of platelet rich plasma therapy is tremendously increased after 2009 due to its
Platelet Agitator Market - Speculation Exploration Report 2027
The report for Platelet Agitator Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The platelet agitator is used for safe and reliable storage of platelets under controlled environment. Platelet agitators are used to keep the platelets under continuous gentle
Platelet Agitator Market new booming trends in 2027
Market Research Future.com add new report of “Platelet Agitator Market Research Report – Global Forecast To 2027” it contains Company information, geographical data and Table of Content Platelet Agitator Market Information, by type (Flatbed, Circular and Combination devices), by capacity (small, medium and large) by end user (autonomous blood banks, hospital based blood banks and others) - Forecast to 2027 The platelet agitator is used for safe and reliable storage of
10-11-2017 | Health & Medicine
TMR
Platelet Rich Plasma Market Size, Share, Analysis & Forecast
With a larger pool of players operating domestically and a smaller bunch of international participants, the global platelet-rich plasma (PRP) market demonstrates a semi-consolidated landscape. The top five players, namely, Harvest Technologies, Arthrex Inc., Zimmer Biomet, DePuy Synthes, and Stryker Corp. accounted for more than 80% of this market in 2015. Most of these are headquartered in North America. However, their focus is likely to shift towards emerging economies across Asia Pacific